Perjeta

Save as Favorite
Sign in to receive recommendations (Learn more)

Perjeta (chemical name: pertuzumab) is approved by the U.S. Food and Drug Administration (FDA) to be used in combination with Herceptin (chemical name: trastuzumab), another targeted therapy medicine, and Taxotere (chemical name: docetaxel), a type of chemotherapy, to treat HER2-positive, metastatic breast cancer that hasn’t been treated with either Herceptin or chemotherapy yet. (Perjeta was called Omnitarg in earlier studies.)

Perjeta also is approved:

  • to be used in combination with Herceptin and Taxotere before surgery to treat HER2-positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high risk of metastasizing or becoming fatal
  • to be used in combination with Herceptin and chemotherapy after surgery to treat HER2-positive, early-stage breast cancer with a high risk of recurrence

Doctors call treatments given before surgery neoadjuvant treatments and treatments given after surgery adjuvant treatments..

In this section you can learn more about:

Join the Conversation


Was this article helpful? Yes / No

Leer esta página en español


Supportpeopleyellow banner mini
Back to Top